|
THURSDAY, DECEMBER 10, 2020 |
|
|
|
|
| 8:45 am - 9:00 am
|
WELCOME AND OVERVIEW |
|
| |
Carlos L. Arteaga, MD
UT Southwestern Medical Center
Simmons Comprehensive Cancer Center
Dallas, TX
Virginia G. Kaklamani, MD
UT Health San Antonio
San Antonio, TX
C. Kent Osborne, MD
Baylor College of Medicine
Houston, TX |
|
| |
|
|
| 9:00 am - 11:30 am |
GENERAL SESSION 3 |
|
| |
|
|
| 9:00 am |
GS3-01.
KEYNOTE-355:
Randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs
placebo + chemotherapy for previously untreated locally recurrent inoperable
or metastatic triple-negative breast cancer
|
|
| |
Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im S, Yusof M, Gallardo C, Lipatov O, Barrios CH, Perez-Garcia J, Iwata H, Masuda N, Otero MT, Gokmen E, Loi S, Guo Z, Zhou X, Karantza V, Pan W, Schmid P. IOB Institute of Oncology, Quiron Group, Madrid & Barcelona, Spain; Princess Margaret Cancer Centre, Toronto, ON, Canada; University of California San Francisco Comprehensive Cancer Center, San Francisco, CA; Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland; Seoul National University Hospital, Seoul, Korea, Republic of; Pantai Hospital, Kuala Lumpur, Malaysia; Arturo Lopez Perez Foundation, Santiago, Chile; Republican Clinical Oncology Dispensary, Republic of Bashkortostan, Russian Federation; Centro de Hematologia e Oncologia, Porto Alegre, Brazil; Hospital Quirónsalud Barcelona, Barcelona, Spain; Aichi Cancer Center Hospital, Nagoya, Japan; National Hospital Organization Osaka National Hospital, Osaka, Japan; Oncomedica S.A., Monteria, Colombia; Ege University Medical Faculty, Izmir, Turkey; Peter McCallum Cancer Institute, Melbourne, Australia; Merck & Co., Inc., Kenilworth, NJ; Barts Cancer Institute, Centre for Experimental Cancer Medicine, London, United Kingdom. |
|
| |
|
|
| 9:15 am |
GS3-02. Primary results
from IMpassion131, a double-blind placebo-controlled randomized phase 3 trial
of paclitaxel ± atezolizumab as first-line therapy for inoperable locally
advanced/metastatic triple-negative breast cancer (mTNBC)
|
|
| |
Miles D, Gligorov J, André F, Cameron D, Schneeweiss A, Barrios C, Xu B, Wardley A, Kaen D, Andrade L, Semiglazov V, Reinisch M, Patre M, Morales L, Russell K, Barata T, O’Shaughnessy J. Mount Vernon Cancer Centre, Northwood, United Kingdom; Institut Universitaire de Cancérologie Assistance Publique – Hôpitaux de Paris-Sorbonne Université, Paris, France; Gustave Roussy, Université Paris Sud, Villejuif, France; University of Edinburgh and Cancer Services, NHS Lothian, Edinburgh, United Kingdom; National Center for Tumor Diseases, University of Heidelberg, Heidelberg, Germany. Latin American Cooperative Oncology Group, Porto Alegre RS, Brazil; National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China; National Institute for Health Research Manchester Clinical Research Facility at The Christie & Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology Medicine & Health, University of Manchester, Manchester, United Kingdom; Centro Oncológico Riojano Integral and Universidad Nacional de La Rioja, La Rioja, Argentina; Santa Casa de Misericordia de Salvador, Salvador, Brazil; NN Petrov Research Institute of Oncology, St Petersburg, Russian Federation; Kliniken Essen-Mitte, Essen, Germany; F. Hoffmann-La Roche Ltd, Basel, Switzerland; Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX. |
|
| |
|
|
| 9:30 am |
GS3-03. Immunotherapy in metastatic TNBC |
|
| |
Discussant: Sylvia Adams, MD
New York University
Perlmutter Cancer Center
New York, NY |
|
| |
|
|
| 9:45 am |
GS3-04.
Double-blind
placebo (PBO)-controlled randomized phase III trial evaluating first-line
ipatasertib (IPAT) combined with paclitaxel (PAC) for PIK3CA/AKT1/PTEN-altered locally advanced unresectable or
metastatic triple-negative breast cancer (aTNBC): primary results from
IPATunity130 Cohort A
|
|
| |
Dent R, Kim S, Oliveira M, Barrios C, O’Shaughnessy J, Isakoff SJ, Saji S, Freitas-Junior R, Philco M, Bondarenko I, Lian Q, Bradley D, Hinton H, Wongchenko MJ, Mani A, Turner N. National Cancer Center, Singapore, Singapore; Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of; Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain; Latin American Cooperative Oncology Group, Porto Alegre RS, Brazil; Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX; Massachusetts General Hospital, Boston, MA; Fukushima Medical University Hospital, Fukushima City, Japan; Hospital Araujo Jorge, Goiania, Brazil; Unidad de Investigación, Instituto de Oncología y Radioterapia, Clínica Ricardo Palma, San Isidro, Peru; City Clinical Hospital No. 4, Dnipropetrovsk, Ukraine; Genentech, Inc., South San Francisco, CA; Roche Products Ltd, Welwyn Garden City, United Kingdom; F Hoffmann-La Roche Ltd, Basel, Switzerland; The Royal Marsden NHS Foundation Trust, and Breast Cancer Now Research Centre, The Institute of Cancer Research, London, United Kingdom. |
|
| |
|
|
| 10:00 am |
GS3-05. Classification of
triple negative breast cancer (TNBC) by DNA Damage Immune Response (DDIR)
signature and Homologous Recombination Deficiency (HRD) status: Analysis of
SWOG S9313 adjuvant trial
|
|
| |
Stecklein SR, Barlow W, Pusztai L, Timms K, Kennedy R, Badve S, Gökmen-Polar Y, Porter P, Linden H, Tripathy D, Hortobagyi GN, Godwin AK, Thompson A, Hayes D, Sharma P. University of Kansas Medical Center, Kansas City, KS; SWOG Statistical Center, Seattle, WA; Yale Cancer Center, New Haven, CT; Myriad Genetics, Inc., Salt Lake City, UT; Almac Group, Craigavon, United Kingdom; Indiana University School of Medicine, Indianapolis, IN; Fred Hutchinson Cancer Research Center, Seattle, WA; University of Washington, Seattle, WA; The University of Texas MD Anderson Cancer Center, Houston, TX; Baylor College of Medicine, Houston, TX; University of Michigan, Ann Arbor, MI; University of Kansas Medical Center, Westwood, KS. |
|
| |
|
|
| 10:15 am |
GS3-06. Biomarker
evaluation in the phase 3 ASCENT study of sacituzumab govitecan versus
chemotherapy in patients with metastatic triple-negative breast
cancer |
|
| |
Hurvitz SA, Tolaney SM, Punie K, Loirat D, Oliveira M, Kalinsky K, Zelnak A, Aftimos P, Dalenc F, Sardesai S, Hamiltion E, Sharma P, Recalde S, Gil EC, Traina T, O'Shaughnessy J, Cortés J, Tsai M, Vahdat L, Diéras V, Carey L, Rugo HS, Goldenberg DM, Hong Q, Olivo M, Itri LM, Bardia A. University of California, Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA; Dana-Farber Cancer Institute, Boston, MA; University Hospitals Leuven, Leuven, Belgium; Institut Curie, Paris, France; Hospital Universitari Vall d'Hebron, Barcelona, Spain; Columbia University Medical Center, New York, NY; Northside Hospital, Atlanta, GA; Institut Jules Bordet, Brussels, Belgium; Institut Claudius Regaud, Toulouse, France; The Ohio State University Wexner Medical Center, Columbus, OH; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; University of Kansas Cancer Center - The Richard and Annette Bloch Cancer Care Pavilion, Kansas City, KS; Institut Catala d'Oncologia Hospitalet, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; Memorial Sloan Kettering Cancer Center, New York, NY; Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, TX; IOB Institute of Oncology, Quiron Group, Madrid & Barcelona, Madrid, Spain; VPCI Oncology Research, Minneapolis, MN; Centre Eugène-Marquis, Rennes, France; University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC; University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Immunomedics, Morris Plains, NJ; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA. |
|
| |
|
|
| 10:30 am |
GS3-07.
Identifying
patients whose symptoms are under-recognized during breast radiotherapy:
comparison of patient and physician reports of toxicity in a multicenter
cohort
|
|
| |
Jagsi R, Griffith KA, Vicini F, Boike T, Dominello M, Gustafson G, Hayman JA, Moran JM, Radawski J, Walker E, Pierce LJ, on behalf of MROQC, the Michigan Radiation Oncology Quality Consortium. University of Michigan, Ann Arbor, MI; MHP Radiation Oncology, Pontiac, MI; MHP Radiation Oncology, Troy, MI; Karmanos, Detroit, MI; Beaumont, Troy, MI; West Michigan Cancer Center, Kalamazoo, MI; Henry Ford, Detroit, MI. |
|
| |
|
|
| 10:45 am |
GS3-08.
Persistent
controlled substance use following mastectomy with reconstruction surgery
|
|
| |
Cogan JC, Raghunathan RR, Beauchemin MP, Accordino MK, Melamed A, Wright JD, Hershman DL. Columbia University Division of Hematology/Oncology, New York, NY; Columbia University Division of Gynecologic Oncology, New York, NY. |
|
| |
|
|
| 11:00 am |
GS3-09.
Chances of
pregnancy after breast cancer, reproductive and disease outcomes: a
systematic review and meta-analysis
|
|
| |
Blondeaux E, Perachino M, Bruzzone M, Anderson RA, De Azambuja E, Poorvu PD, Kim HJ, Villarreal-Garza C, Pistilli B, Vaz-Luis I, Saura C, Ruddy KJ, Franzoi MA, Sertoli C, Ceppi M, Azim Jr. HA, Amant F, Demeestere I, Del Mastro L, Partridge AH, Pagani O, Peccatori FA, Lambertini M. IRCCS Ospedale Policlinico San Martino, Genova, Italy; The Queen's Medical Research Institute, The University of Edinburgh, Edinburgh, United Kingdom; Institut Jules Bordet, Université Libre de Bruxelles (U.L.B.), Brussels, Belgium; Dana-Farber Cancer Institute, Boston, MA; Asan Medical Center, Seoul, Korea, Republic of; Hospital Zambrano Hellion, Tecnologico de Monterrey, San Pedro Garza Garcia, Mexico; Institut Gustave Roussy, Villejuif, France; Vall d´Hebron University Hospital (HUVH), Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spain; Mayo Clinic, Rochester, MN; University of Genova, Genova, Italy; Hospital Zambrano Hellion, Tecnologico de Monterrey, San Pedro Garza Garcia, Mexico; Netherlands Cancer Institute and Amsterdam University Medical Centers, Amsterdam, Netherlands; Erasme Hospital, Université Libre de Bruxelles (U.L.B.), Brussels, Belgium; Breast Unit and Institute of Oncology of Southern Switzerland, Geneva University Hospitals, Swiss Group for Clinical Cancer Research, Lugano, Switzerland; European Institute of Oncology IRCCS, European School of Oncology, Milano, Italy. |
|
| |
|
|
| 11:15 am |
GS3-10.
Partitioning of
cancer therapeutics in nuclear condensates
|
|
| |
Klein I, Boija A, Afeyan L, Hawken SW, Fan M, Dall'Agnese A, Oksuz O, Henninger J, Shrinivas K, Sabari B, Sagi I, Clark V, Platt J, Kar M, McCall P, Zamudio A, Mantiega J, Coffey E, Li C, Hannett N, Guo Y, Decker TM, Lee T, Zhang T, Weng J, Taatjes D, Chakraborty A, Sharp P, Chang YT, Hyman A, Gray N, Young R. Dana Farber Cancer Institute, Boston, MA; Whitehead Institute, Cambridge, MA; Massachusetts Institute of Technology, Cambridge, MA; Massachusetts General Hospital, Boston, MA; Max Plank Institute, Dresden, Germany; University of Colorado, Boulder, CO; POSTECH, Pohang, Korea, Republic of. |
|
| |
|
|
| 10:00 am - 3:00 pm |
EXHIBITS |
|
| |
|
|
| 11:30 am - 12:30 pm |
DEBATE |
|
| |
All Breast Cancer Patients Should Have Germline Genetic Testing |
|
| |
Moderator: Virginia G. Kaklamani, MD
UT Health San Antonio
San Antonio, TX
For
Mark Robson, MD
Memorial Sloan Kettering Cancer Center
New York, NY
and
Judy E. Garber, MD, MPH
Dana-Farber Cancer Institute
Boston, MA
Against
Judith Balmaña, MD, PhD
Vall D'Hebron University Hospital
Barcelona, Spain
and
Allison Kurian, MD, MSc
Stanford University
Stanford, CA
|
|
| |
|
|
| 12:30 pm - 1:00 pm |
BREAK |
|
| |
|
|
| 1:00 pm - 2:15 pm
|
SPOTLIGHT SESSION 4: Updates on Strategies to Refine Management of the Axilla
|
|
| |
|
|
| |
SPOTLIGHT SESSION 7: Examining Early Events: Novel Models and Neoadjuvant Events
|
|
| |
|
|
| 2:15 pm - 3:30 pm |
SPOTLIGHT SESSION 5: Current Concepts and Controversies in Ductal Carcinoma in Situ (DCIS) |
|
| |
|
|
| |
|
|
| |
SPOTLIGHT SESSION 8: Endocrine Resistance: Emerging Mechanisms and Therapies |
|
| |
|
|
| |
|
|
| 3:30 pm - 4:45 pm
|
SPOTLIGHT SESSION 6: Novel Approaches to Pathology and Imaging |
|
| | |
|
| |
|
|
| |
SPOTLIGHT SESSION 9: Challenging Indications and Innovative Approaches for Biomarkers |
|
| |
|
|
|
|
|
|
| 7:30 pm |
OPEN SATELLITE EVENT presented by Physicians' Education Resource, LLC
The Next Frontier: Meeting Unmet Clinical Needs in the Treatment of Breast Cancer Brain Metastases
|
|
| |
|
|
| 7:30 pm |
OPEN SATELLITE EVENT presented by Clinical Care Options, LLC
Evolving Clinical Considerations for Breast Cancer Brain Metastases: Expert Case Discussions
|
|
|